Peter Kolchinsky graduated from Harvard with a Ph.D. in virology in 2001. After graduation he got $4 Million from Vertex Pharma co-founder Rich Aldrich and started picking biotech stocks at RA Capital. In 2002 he broke even when the S&P 500 index lost 22%. By the end of 2003, the initial $4 Million investment became $13 Million. Boston-based RA Capital invests in companies with promising drugs and technologies.
| Fund Name: | RA Capital Management |
| Manager | Peter Kolchinsky |
| Portfolio Value | $1,305,208,000 |
| Change This QTR | +1.09% |
| No. | Security | Ticker | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|---|
| 1. | Wave Life Sciences Ltd | 7,512,049 | $301,233 | 23.07% | ||
| 2. | ASND | 4,240,536 | $277,331 | -25% | 21.24% | |
| 3. | Avexis Inc | 1,028,289 | $127,076 | -13% | 9.73% | |
| 4. | Myovant Sciences Ltd | 2,830,455 | $60,204 | 4.61% | ||
| 5. | Sage Therapeutics Inc | 353,133 | $56,879 | -23% | 4.35% |
| Company | Symbol | Filed By | Filing Date | Filing |
|---|---|---|---|---|
| 2018-04-26 | ||||
| 2018-04-02 | ||||
| 2018-03-27 | ||||
| 2018-02-16 |
